Answers are grounded in this paper and cite their sources.
The increasing prevalence of cancer has driven the search for targeted and effective therapeutic approaches with reduced side effects. Nanotechnology-based drug delivery systems have emerged as promising platforms for cancer therapy due to their enhanced biocompatibility and therapeutic efficiency. In this study, hyaluronic acid-functionalized gold–cerium oxide nanocomposites (HA-Au-CeO₂ NCs) were synthesized and evaluated for their anticancer potential against MCF-7 breast cancer cells by inducing apoptosis via the caspase-3 pathway. Physicochemical characterization confirmed the successful surface decoration and functionalization of CeO₂ cores with Au and HA, maintaining the core crystalline fluorite framework with a median particle size of 72.69 nm. Cytotoxicity analysis demonstrated that HA-Au-CeO₂ exhibited significantly greater anticancer activity against MCF-7 cells compared to pristine CeO₂ and Au-CeO₂ nanoparticles, with IC₅₀ values of 111.4, 158.6, and 381.3 µg/mL, respectively (p < 0.001). AO/PI staining and flow cytometry analyses revealed concentration-dependent apoptosis, with more than 50% secondary apoptosis observed at 500 µg/mL. In addition, caspase-3 upregulation confirmed activation of the mitochondrial apopotic pathway. These findings indicate that the synthesized HA-Au-CeO₂ nanocomposites demonstrated potent anticancer activity by significantly reducing breast cancer cell viability and inducing apoptosis through caspase-3 activation. The enhanced therapeutic performance and biocompatibility of the nanocomposite highlight its potential as a promising targeted nanotherapeutic platform for breast cancer treatment.
No takes yet. Share an insight, caveat, or question.
Abedi et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: